Determination of Myc Genes Mutations in Patients with Leukemia from Turkey
Myc oncogenes are contributing to the development of cancer, and many of the genes to become active. Studies on the expression of these genes have led to the development of new therapies for the treatment of cancer patients. This situation was quickly discovered that A pioneer or biomarker Myc expression triggers the differentiation and proliferation of cells as mitogenindependent, especially. Myc activation was a consequence of mutations in the coding sequence. Mutations in the coding sequence were observed in 4 of the 50 leukemia specimens. Four mutations which is named SNP (rs3134614, rs1800834, rs61731506, rs74067837), in exon 2 mutations. DNA sequencing reveals that A, G, C, and T formed in exon 2 of the L-myc gene. Any change has been determined at exon 1. A point mutation or single point mutations called SNP contains an incorrect base pairing. In addition to, seeing if the point mutations of L-Myc have acute leukemias, or acute leukemia patients with the existence point mutations of L-Myc gene we analyzed by the gene sequence assay and Polymerase Chain Reaction-based Single-Strand Conformation Polymorphism (PCR-SSCP) assay. In the study, the mutation observed in patients with leukemia has proven to be the most common type of L-Myc mutations, consistent with the literature. There is significant difference in the genotype distribution between leukemia patients and controls was observed. Our results suggested that L-Myc gene polymorphism was a suitable prognostic marker in the identification of metastatic growth chronic lymphocytic leukemia (CLL) and acute myeloblastic leukemia (AML) in Turk populations.
Hasibe Cingilli Vural